Sfoglia per AUTORE
SIENA S
Collezione AO Ordine Mauriziano

  

Items : 6

Correction to: A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY tract cancers (BTC) at high risk for recurrence: PURITY study. in BMC cancer / BMC Cancer. 2024 May 6;24(1):563. doi: 10.1186/s12885-024-12328-0.

2024
AO Ordine Mauriziano

Mazzaferro V; Arcangeli G; Corallo S; Delliponti L; Pietrantonio F; Di Bartolomeo M; Sposito C; Busset MDD; Martinetti A; Sottotetti E; Cavallo I; Ljevar S; Miceli R; Baili P; Rapposelli IG; Salati M; Brandi G; Fea E; Tamberi S; Niger M; Longarini R; Mosconi S; Bergamo F; Siena S; Melisi D; Salvatore L; Sperti E; Gardini AC; Berardi R; et alii...

A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY Tract Cancers (BTC) at high risk for recurrence: PURITY study. in BMC cancer / BMC Cancer. 2024 Apr 8;24(1):436. doi: 10.1186/s12885-024-12225-6.

2024
AO Ordine Mauriziano

Mazzaferro V; Pietrantonio F; Di Bartolomeo M; Sposito C; Busset MDD; Martinetti A; Sottotetti E; Cavallo I; Ljevar S; Miceli R; Salati M; Baili P; Rapposelli IG; Brandi G; Fea E; Tamberi S; Delliponti L; Corallo S; Arcangeli G; Mosconi S; Longarini R; Niger M; Nichetti F; Fornaro L; Siena S; Melisi D; Bergamo F; Salvatore L; Sperti E; et alii...

BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors. in Cancer research / Cancer Res. 2023 May 15;83(10):1699-1710. doi: 10.1158/0008-5472.CAN-22-2620.

2023
ASL Alessandria
AO Ordine Mauriziano

Petrelli A; Berrino E; Romagnoli D; Benelli M; De Cecco L; Bellomo SE; Rizzolio S; Pietrantonio F; Orrù C; Ribisi S; Moya-Rull D; Migliore C; Conticelli D; Maina IM; Puliga E; Serra V; Pellegrino B; Llop-Guevara A; Musolino A; Siena S; Sartore-Bianchi A; Prisciandaro M; Morano F; Antista M; Fumagalli U; De Manzoni G; Degiuli M; Baiocchi GL; Amisano MF; et alii...

A validated prognostic classifier for V600EBRAF-mutated metastatic colorectal cancer: the ‘BRAF BeCool’ study in European Journal of Cancer

2019
AO Ordine Mauriziano

Biason P; Lonardi S; Zagonel V; Fassan M; Di Maio M; Buggin F; Prete AA; Depetris I; Morano F; Ongaro E; Cascinu S; Santini D; Ziranu P; Schirripa M; Salvatore L; Calegari MA; Siena S; Prenen H; Negri F; Di Donato S; Buonandi P; Tomasello G; Avallone A; Zustovich F; Moretto R; Antoniotti C; Aprile G; Antonuzzo L; Urbano F; et alii...

Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial. in Annals of oncology : official journal of the European Society for Medical Oncology / Ann Oncol. 2012 May;23(5):1185-1189. doi: 10.1093/annonc/mdr441. Epub 2011 Oct 5.

2012
AO Ordine Mauriziano

Gladieff L; Ferrero A; De Rauglaudre G; Brown C; Vasey P; Reinthaller A; Pujade-Lauraine E; Reed N; Lorusso D; Siena S; Helland H; Elit L; Mahner S;

A molecularly annotated platform of patient- derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer in Cancer Discovery

2011
AO Ordine Mauriziano

Bertotti A; Migliardi G; Galimi F; Sassi F; Torti D; Isella C; Corà D; di Nicolantonio F; Buscarino M; Petti C; Ribero D; Russolillo N; Muratore A; Massucco P; Pisacane A; Molinaro L; Valtorta E; Sartore-Bianchi A; Risio M; Capussotti L; Gambacorta M; Siena S; Medico E; Sapino A; Marsoni S; Comoglio PM; Bardelli A; Trusolino L;